Hycult Biotech designs, develops, produces and markets antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields, with an emphasis on complement, neutrophil proteins, TLR, scavenger receptors and acute phase proteins. Furthermore, we have a strong interest in progressing research in the area of inflammation and cell damage caused by pathogens or oxidation factors.
Hycult Biotech’s mission and strategy is to advance insight in innate immunity related diseases, for the benefit of individuals and their quality of life.
As a leader within focused fields of immunology and cell biology, we develop products for the life sciences and in accordance with our mission it is our ambition to facilitate the transition of these products from research use into diagnostic testing. Many of our reagents are developed in close cooperation with scientists worldwide. Hycult Biotech has built a strong network with over 40 close scientific collaborations with leading international research institutes. We contribute to numerous projects and as a result, can continuously offer early access to an expanding range of innovative reagents. Hycult Biotech has been ISO-9001 certified since 1998 and we upgraded our certification to ISO-13485 in 2007, with a milestone of our first release of CE marked assays in 2009. Our vision, knowledgeable team and quality management system guarantee products of the highest grade combined with excellent technical service.
Hycult Biotech Inc. names Executive Director to Board
PLYMOUTH MEETING, Pa- January 06, 2011. Hycult Biotech Inc., a wholly owned Subsidiary of Hycult Biotech B.V., a provider of innovative immunology and cell biology solutions, has named Mr. Dino DiCamillo as Executive Director, of its newly incorporated U.S. Subsidiary.
“As a business leader and industry expert, Mr. DiCamillo brings to Hycult Biotech Inc. a deep understanding of operations necessary to support a local subsidiary”
.Mr. DiCamillo brings extensive expertise and experience in the areas of immunology, genomics, proteomics, and business operations and management. He currently serves as President and CEO of Percorso Life Sciences, where he partners with early stage technology companies and provides direction and leadership to companies looking to establish a U.S. presence. More recently, Mr. DiCamillo served as Vice President and Officer of Advanced Research Technologies, President of Alfa Wassermann Proteomics, Vice President of Environmental Diagnostics at Invitrogen, and President of Dynal Biotech Inc, where he provided strategic leadership and execution in a variety of roles.
"As a business leader and industry expert, Mr. DiCamillo brings to Hycult Biotech Inc. a deep understanding of operations necessary to support a local subsidiary," said Mr. Rik van Heijningen, Managing Director of Hycult Biotech B.V. "His expertise with new technology adoption, operations, and channel management will assist Hycult Biotech Inc. execute its local strategy."
"I am proud to play a role in the development and execution of Hycult’s local strategy,” said Mr. DiCamillo. "Hycult Biotech offers a broad and unique technology specific to researchers who focus on the innate immune system, which facilitates the understanding of the immune system paradigm."
Hycult Biotech b.v. Announces Formation of Hycult Biotech Inc. to Serve the Innate Immune Market Segment in the Americas
Uden, The Netherlands, December 1, 2010 – Hycult Biotechnology bv (Hycult Biotech) announced today the formation of Hycult Biotech Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. The Company specializes in the development, manufacturing and commercialization of antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields. Read more
Hycult Biotech announces establishment of Scientific Advisory Board
23 of August, 2010 -Uden, The Netherlands. -Hycult Biotechnology BV (Hycult Biotech), a biotechnology company and a leader in the development of innovative and new Innate Immunity Life Sciences reagents announces the establishment of its Scientific Advisory Board (SAB). The SAB will further guide the Company in its scientific development and focus within the field of Innate Immunity. Read more
Cardiff University and Hycult Biotech entering an exclusive deal for factor H variant assay (April 2009)
Hycult Biotech (HB) has obtained the exclusive rights from Cardiff University for the development of a factor H variant (Y402/H402) research assay. This unique tool is developed in close collaboration between Prof. Paul Morgan (dept. Medical Biochemistry and Immunology) at Cardiff University and the R&D department of HB and is developed within 5 months after signing the agreement. Read more
If you as scientist are interested in a collaboration or commercialization of any of your reagents please contact Loek Willems at: l.willems@hycultbiotech.com
As a fast growing company we are continuously looking for new talent.
We invite well trained, motivated candidates to contact us by a written application.
Send your CV to:
Hycult Biotech
Attn. Mw. J. Verzijl
P.O. box 30
5400 AA Uden – The Netherlands
Or e-mail the CV to:
j.verzijl@hycultbiotech.com
Hycult Biotech participates in the following research projects:
TranSVIR
Hycult Biotech participates in study on novel biomarker detection for vascular inflammation
for more information see: TranSVIR.pdf
CTMM
Biomarkers for the Prediction and Early Diagnosis of Diabetes and Diabetes-related Cardiovascular Complications (PREDICCt)
for more information see: Predicct.pdf
Intricate
Hycult Biotech participates in study on infections in relation to chronic autoimmunity
November 2010, Hycult Biotech (HB) has started participating in a European study on chronic autoimmunity. INTRICATE is a multidisciplinary European Consortium of scientists, clinical investigators and physicians collaborating in the fields of autoimmunity and infections. The current proposal is founded on the initiative of HEALTH.2010.2.4.5-2: Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases and its goals are to meet the challenge of unraveling the mechanisms and the role of bacterial infection in the initiation and development of human autoimmune disease.
More information